AbbVie, Inc. (ABBV) has entered into a definitive agreement to acquire Aliada Therapeutics, a biotechnology firm, for $1.4 billion in cash. This transaction includes customary adjustments and will result in AbbVie obtaining all outstanding equity of Aliada.
Aliada's leading investigational product, ALIA-1758, uses a delivery technology designed for the treatment of Alzheimer's disease. ALIA-1758 is a monoclonal antibody targeting the pyroglutamate-modified amyloid beta (3pE-Aß).
Aliada is at the forefront of developing therapeutic drugs through its Modular Delivery (MODEL) platform, which is specifically engineered for precise central nervous system (CNS) drug delivery.
This acquisition will enable AbbVie to leverage Aliada's innovative blood-brain barrier (BBB) technology to advance its research and development initiatives in the field of neuroscience.
The transaction is anticipated to be finalized in the fourth quarter of 2024, pending regulatory approvals and other standard closing conditions.
